|
1
|
Ezzat S, Asa SL, Couldwell WT, Barr CE,
Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary
adenomas: A systematic review. Cancer. 101:613–619. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heaney AP and Melmed S: Molecular targets
in pituitary tumours. Nat Rev Cancer. 4:285–295. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Melmed S: Medical progress: Acromegaly. N
Engl J Med. 355:2558–2573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toledo RA, Lourenço DM Jr, Liberman B,
Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP and Dahia PL:
Germline mutation in the aryl hydrocarbon receptor interacting
protein gene in familial somatotropinoma. J Clin Endocrinol Metab.
92:1934–1937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daly AF, Tichomirowa MA and Beckers A:
Genetic, molecular and clinical features of familial isolated
pituitary adenomas. Horm Res. 71:116–122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pierantoni GM, Finelli P, Valtorta E,
Giardino D, Rodeschini O, Esposito F, Losa M, Fusco A and Larizza
L: High-mobility group A2 gene expression is frequently induced in
non-functioning pituitary adenomas (NFPAs), even in the absence of
chromosome 12 polysomy. Endocr Relat Cancer. 12:867–874. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dworakowska D and Grossman AB: The
pathophysiology of pituitary adenomas. Best Pract Res Clin
Endocrinol Metab. 23:525–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vierimaa O, Georgitsi M, Lehtonen R,
Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM,
Salmela PI, Paschke R, et al: Pituitary adenoma predisposition
caused by germline mutations in the AIP gene. Science.
312:1228–1230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu R, Bonert V, Saporta I, Raffel LJ and
Melmed S: Aryl hydrocarbon receptor interacting protein variants in
sporadic pituitary adenomas. J Clin Endocrinol Metab. 91:5126–5129.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Daly AF, Jaffrain-Rea ML, Ciccarelli A,
Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B,
Ciccarelli E, Brue T, et al: Clinical characterization of familial
isolated pituitary adenomas. J Clin Endocrinol Metab. 91:3316–3323.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Daly AF, Vanbellinghen JF, Khoo SK,
Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P,
Gimenez-Roqueplo AP, Tamburrano G, et al: Aryl hydrocarbon
receptor-interacting protein gene mutations in familial isolated
pituitary adenomas: Analysis in 73 families. J Clin Endocrinol
Metab. 92:1891–1896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DiGiovanni R, Serra S, Ezzat S and Asa SL:
AIP mutations are not identified in patients with sporadic
pituitary adenomas. Endocr Pathol. 18:76–78. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Georgitsi M, Heliövaara E, Paschke R,
Kumar AV, Tischkowitz M, Vierimaa O, Salmela P, Sane T, De Menis E,
Cannavò S, et al: Large genomic deletions in AIP in pituitary
adenoma predisposition. J Clin Endocrinol Metab. 93:4146–4151.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Igreja S, Chahal HS, Akker SA, Gueorguiev
M, Popovic V, Damjanovic S, Burman P, Wass JA, Quinton R, Grossman
AB and Korbonits M: Assessment of p27 (cyclin-dependent kinase
inhibitor 1B) and aryl hydrocarbon receptor-interacting protein
(AIP) genes in multiple endocrine neoplasia (MEN1) syndrome
patients without any detectable MEN1 gene mutations. Clin
Endocrinol (Oxf). 70:259–264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ozfirat Z and Korbonits M: AIP gene and
familial isolated pituitary adenomas. Mol Cell Endocrinol.
326:71–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toledo RA, Mendonca BB, Fragoso MC, Soares
IC, Almeida MQ, Moraes MB, Lourenço DM Jr, Alves VA, Bronstein MD
and Toledo SP: Isolated familial somatotropinoma: 11q13-LOH and
gene/protein expression analysis suggests a possible involvement of
AIP also in non-pituitary tumorigenesis. Clinics (Sao Paulo).
65:407–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chahal HS, Stals K, Unterländer M, Balding
DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ,
Howlett TA, et al: AIP mutation in pituitary adenomas in the 18th
century and today. N Engl J Med. 364:43–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bell DR and Poland A: Binding of aryl
hydrocarbon receptor (AhR) to AhR-interacting protein. The role of
hsp90. J Biol Chem. 275:36407–36414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu YZ, Hogenesch JB and Bradfield CA: The
PAS superfamily: Sensors of environmental and developmental
signals. Annu Rev Pharmacol Toxicol. 40:519–561. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oesch-Bartlomowicz B, Huelster A, Wiss O,
Antoniou-Lipfert P, Dietrich C, Arand M, Weiss C, Bockamp E and
Oesch F: Aryl hydrocarbon receptor activation by cAMP vs. dioxin:
Divergent signaling pathways. Proc Natl Acad Sci USA.
102:9218–9223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bolger GB, Peden AH, Steele MR, MacKenzie
C, McEwan DG, Wallace DA, Huston E, Baillie GS and Houslay MD:
Attenuation of the activity of the cAMP-specific phosphodiesterase
PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem.
278:33351–33363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jennings JE, Georgitsi M, Holdaway I, Daly
AF, Tichomirowa M, Beckers A, Aaltonen LA, Karhu A and Cameron FJ:
Aggressive pituitary adenomas occurring in young patients in a
large Polynesian kindred with a germline R271W mutation in the AIP
gene. Eur J Endocrinol. 161:799–804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Naves LA, Jaffrain-Rea ML, Vêncio SA,
Jacomini CZ, Casulari LA, Daly AF and Beckers A: Aggressive
prolactinoma in a child related to germline mutation in the ARYL
hydrocarbon receptor interacting protein (AIP) gene. Arq Bras
Endocrinol Metabol. 54:761–767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pinho LK, Neto Vieira L, Wildemberg LE,
Moraes AB, Takiya CM, Frohman LA, Korbonits M and Gadelha MR:
Familial isolated pituitary adenomas experience at a single center:
Clinical importance of AIP mutation screening. Arq Bras Endocrinol
Metabol. 54:698–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Villa C, Lagonigro MS, Magri F, Koziak M,
Jaffrain-Rea ML, Brauner R, Bouligand J, Junier MP, Di Rocco F,
Sainte-Rose C, et al: Hyperplasia-adenoma sequence in pituitary
tumorigenesis related to aryl hydrocarbon receptor interacting
protein gene mutation. Endocr Relat Cancer. 18:347–356. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tichomirowa MA, Barlier A, Daly AF,
Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P,
Elenkova A, Tabarin A, et al: High prevalence of AIP gene mutations
following focused screening in young patients with sporadic
pituitary macroadenomas. Eur J Endocrinol. 165:509–515. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cazabat L, Bouligand J, Salenave S,
Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A and
Chanson P: Germline AIP mutations in apparently sporadic pituitary
adenomas: Prevalence in a prospective single-center cohort of 443
patients. J Clin Endocrinol Metab. 97:E663–E670. 2012. View Article : Google Scholar : PubMed/NCBI
|
